Copyright
©2010 Baishideng. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2010; 2(1): 19-30
Published online Jan 15, 2010. doi: 10.4251/wjgo.v2.i1.19
Published online Jan 15, 2010. doi: 10.4251/wjgo.v2.i1.19
Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer
Paul H Sugarbaker, O Anthony Stuart, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, United States
Kurt Van der Speeten, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium
Author contributions: Sugarbaker PH, Stuart OA and Van der Speeten K performed the research; Sugarbaker PH, Stuart OA and Van der Speeten K analyzed the data; Sugarbaker PH, Stuart OA and Van der Speeten K wrote the paper.
Correspondence to: Paul H Sugarbaker, MD, FACS, FRCS, Washington Cancer Institute, Washington Hospital Center, 106 Irving St., NW, Suite 3900, Washington, DC 20010, United States. paul.sugarbaker@medstar.net
Telephone: +1-202-8773908 Fax: +1-202-8778602
Received: July 2, 2009
Revised: August 28, 2009
Accepted: September 5, 2009
Published online: January 15, 2010
Revised: August 28, 2009
Accepted: September 5, 2009
Published online: January 15, 2010
Core Tip